A Study of K-333 (peretinoin) in Patients with Complete Cure of Hepatitis B Virus (HBV)-Positive Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222099

Enrollment

100

Registered

2013-06-07

Start date

2013-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of the recurrence of HCC in patients with complete cure of HBV-positive HCC

Interventions

investigational material(s) Generic name etc : K-333 INN of investigational material : Peretinoin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with HBV-positive HCC of the first primary or the first recurrence of primary HCC (2)Patients showing that a complete cure was confirmed by either local ablation or surgical resection (3)Patients of the age of 20 years or older at the time of informed consent etc.

Exclusion criteria

Exclusion criteria: Patients who received the radical therapy to HCV-related HCC etc.

Design outcomes

Primary

Measure	Time frame
efficacy exploratory Recurrence-free survival Time to recurrence of HCC or death, regardless of cause	—

Secondary

Measure	Time frame
efficacy (1)Disease-free survival (2)Time to recurrence (1)Time to recurrence of HCC, death, regardless of cause, or occurrence of secondary cancer (2)Time to recurrence of HCC	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026